Fig. 1From: The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancerReceiver operating characteristic curves of total CTC count and the proportion of M + CTCs for predicting 1-year PFS rate. CTC circulating tumor cell, M + CTCs mesenchymal CTCs, PFS progression-free survivalBack to article page